Water-activated, pH-controlled patch in transdermal administration of timololII. Drug absorption and skin irritation

European Journal of Pharmaceutical Sciences

Volumn 11, Issue 1, 2000, Pages 25-31

  Sutinen, Riitta ^a   Paronen, Petteri ^a   Saano, Veijo ^b   Urtti, Arto ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b NATIONAL AGENCY FOR MEDICINES   (Finland)

Author keywords

Drug absorption; Silicone; Skin irritation; Stella( ) simulations; Timolol; Transdermal patch

Indexed keywords

SILICONE; TIMOLOL; TIMOLOL MALEATE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; FEMALE; HUMAN; MALE; NORMAL HUMAN; PH; PRIORITY JOURNAL; SKIN IRRITATION; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADRENERGIC BETA-ANTAGONISTS; ADULT; EXANTHEMA; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; SILICONE ELASTOMERS; SKIN ABSORPTION; TIMOLOL;

EID: 0034086473     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(00)00083-X     Document Type: Article

References (21)

1. Babulak S.W., Rhein L.D., Scala D.D., Simion F.A., Grove G.L. Quantitation of erythema in a soap chamber test using the Minolta chroma (reflectance) meter: comparison of instrumental results with visual assessment. J. Soc. Cosmet. Chem. 37:1986;475-479.
2. Benet L.Z., Williams R.L. Design and optimization of dosage regimens: pharmacokinetic data. Goodman-Gilman L.S., Gilman A. The Pharmacological Basis of Therapeutics. 1990;1650-1735 MacMillan, New York.
3. Berner B., Mazzenga G.C., Gargiulo P.M., Steffens R. A transdermal nicotine system: feasibility studies. J. Contr. Rel. 20:1992;13-20.
4. Brain K.R., Hadgraft J., James V.J., Shah V.P., Walters K.A., Watkinson A.C. In vitro assessment of skin permeation from a transdermal system for the delivery of oestradiol. Int. J. Pharm. 89:1993;R13-R16.
5. Cargill R., Engle K., Rork G., Caldwell L.J. Systemic delivery of timolol after dermal application: Transdermal flux and skin irritation potential in the rat and dog. Pharm. Res. 3:1986;225-229.
6. Eller M.G., Schoenwald R.D., Dixson J.A., Segarra T., Barfknecht C.F. Topical carbonic anhydrate inhibitors: IV. Relationship between excised corneal permeability and pharmacokinetic factors. J. Pharm. Sci. 74:1985;525-529.
7. Elsner M.G., Wilhelm D., Maibach H.I. Multiple parameter assessment of vulvar irritant contact dermatitis. Contact Dermatitis. 23:1990;20-26.
8. Guy R.H., Hadgraft J. Rate control in transdermal drug delivery? Int. J. Pharm. 82:1992;R1-R6.
9. Hirvonen J., Sutinen R., Paronen P., Urtti A. Transdermal penetration enhancement in rabbit pinna skin: Duration of action, skin irritation, and in vivo/in vitro comparison. Int. J. Pharm. 99:1993;253-261.
10. Hurkmans J.F.G.M., Boddé H.E., van Driel L.M.J., van Doorne H., Junginger H.E. Skin irritation caused by transdermal drug delivery system during long-term (5 days) application. Br. J. Dermatol. 112:1985;461-465.
11. Ishizaki T., Tawara K., Oyama Y., Nakaya H. Clinical pharmacologic observations on timolol. I. Disposition and effect in relation to plasma level in normal individuals. J. Clin. Pharmacol. 18:1978;511-518.
12. Kaila T. A sensitive radioligand binding assay for timolol in plasma. J. Pharm. Sci. 80:1991;296-299.
13. Kubota K., Koyama E., Yasuda K. Skin irritation induced by topically applied timolol. Br. J. Clin. Pharmacoc. 31:1991;471-475.
14. McCrea J.B., Vlasses P.H., Franz T.J., Zeoli L. Transdermal timolol: β-blockade and plasma concentrations after application for 48 h and 7 days. Pharmacotherapy. 10:1990;289-293.
15. Pershing L.K., Lambert L.D., Shah V.P., Lam S.Y. Variability and correlation of chromameter and tape-stripping methods with the visual skin blanching assay in the quantitative assessment of topical 0.05% betamethasone dipropionate bioavailability in humans. Int. J. Pharm. 86:1992;201-210.
16. Seitz J.C., Whitmore C.G. Measurement of erythema and tanning responses in human skin using a tri-stimulus colorimeter. Dermatologica. 177:1988;70-75.
17. Sutinen, R., Paronen, P., Urtti, A. 2000. Water-activated and pH-controlled patch in transdermal administration of timolol. I. Preclinical tests. Eur. J. Pharm. Sci. submitted for publication.
18. Urtti A., Kyyrönen K. Ophthalmic epinephrine, phenylephrine, and pilocarpine affect the systemic absorption of ocularly applied timolol. J. Ocul. Pharmacol. 5:1989;127-132.
19. Wellstein A., Palm D., Wiemer G., Schäfer-Korting M., Mutschler E. Simple and reliable radioreceptor assay for β-adrenoreceptorantagonists and active metabolites in native human plasma. Eur. J. Clin. Pharmacol. 27:1984;545-553.
20. Vermeij P., el Sherbini-Schepers M., van Zwieten P.A. The diposition of timolol in man. J. Pharm. Sci. 30:1978;53-55.
21. Vlasses P.H., Ribeiro L.G.T., Rotmensch H.H., Bondi J.V., Loper A.E., Hichens M., Dunlay M.C., Ferguson R.K. Initial evaluation of transdermal timolol: Serum concentrations and β-blockade. J. Cardiovasc. Pharmacol. 7:1985;245-250.